COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
about
DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation.Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell LineCo-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the BreastADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Ductal carcinoma in situ - update on risk assessment and management.Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.Copy number analysis of ductal carcinoma in situ with and without recurrence.Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density.
P2860
Q36349712-732C1510-95A7-4341-B063-EE544B645473Q36407288-09D0E6C3-5CD5-4349-8966-644FDCDC588EQ36914879-79D2C29B-9E43-4B32-A310-8E42297C67EFQ37329011-143202B5-1AA6-4E91-9576-8B3C85281C19Q37709099-9DD66A53-9621-46C6-AC03-1B2A3EAF8DECQ38451287-5C90CFA9-01D6-48B0-9759-2E320866E65AQ38550876-4D73343F-41C6-45D5-8E89-10F8074DB349Q38582873-87FC23A7-3701-489F-AB14-983416B15A49Q38696796-5C787D5C-91BB-41D9-A164-5C6F072E756AQ44221870-96E539CF-B9C5-427A-BCDF-0AA7DEAA44F8Q46699535-B41C2268-E86A-4995-B7D4-98841C3E2D9DQ48140150-F0DFDFCD-EEE1-4E9E-A79B-7334EB493ED0Q53400538-94FFCF6B-5538-404A-A96A-31B54CFC9E69
P2860
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
COX-2 expression is predictive ...... and is a target for treatment
@ast
COX-2 expression is predictive ...... and is a target for treatment
@en
type
label
COX-2 expression is predictive ...... and is a target for treatment
@ast
COX-2 expression is predictive ...... and is a target for treatment
@en
prefLabel
COX-2 expression is predictive ...... and is a target for treatment
@ast
COX-2 expression is predictive ...... and is a target for treatment
@en
P2093
P2860
P356
P1476
COX-2 expression is predictive ...... and is a target for treatment
@en
P2093
A L Harris
D Generali
M Cummings
P2860
P2888
P356
10.1038/BJC.2014.236
P407
P577
2014-05-29T00:00:00Z
P5875
P6179
1025933741